ARQT - NASDAQ
Arcutis Biotherapeutics, Inc.
$21.35
-0.56%Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
At a Glance
Live Snapshotarqt
Cash at Beginning of Period
Last Annual Value
71.95M
3-Year CAGR
-10%
5-Year CAGR
3%
10-Year CAGR
99%
Arcutis Biotherapeutics, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Arcutis Biotherapeutics, Inc. NASDAQ:ARQT | 71.95M | 9.5% | 1.6% | N/A | |
 Celcuity Inc. NASDAQ:CELC | 22.52M | -2.9% | 14.1% | 16.1% | |
 Travere Therapeutics, Inc. NASDAQ:TVTX | 58.53M | -1.7% | -7.1% | 4.5% | |
 Disc Medicine, Inc. NASDAQ:IRON | 192.67M | -0.4% | 49.4% | N/A | |
 Tarsus Pharmaceuticals, Inc. NASDAQ:TARS | 97.38M | 10.8% | -10.3% | N/A | |
 CG Oncology, Inc. Common stock NASDAQ:CGON | 257.07M | 42.9% | 37.7% | N/A | |
 Legend Biotech Corporation NASDAQ:LEGN | 286.82M | -28.5% | -8.8% | N/A | |
 Amicus Therapeutics, Inc. NASDAQ:FOLD | 216.72M | 12.3% | 5.5% | 12.0% |
Arcutis Biotherapeutics, Inc. Fair Value Envelope
Related Guides
Continue your ARQT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.